Accel Diagnostics

Home Monitor for Congestive Heart Failure
Accel is currently focusing on its first product: pScreen-BNP™: the first not-implantable daily home test for the monitoring of heart failure patients. BNP is a cardiac biomarker known for its specificity and sensitivity in the diagnosis of Congestive Heart Failure (CHF).

Accel’s solution marks a paradigm shift in the management of CHF and presents a nearly $3 Billion opportunity. It allows for the first time, CHF patients to frequently monitor their level of heart distress, outside the clinical setting, in the comfort of their home.

Accel’s solution enables patients and their physicians to respond before physical symptoms occur, preventing otherwise frequent life threatening events and costly reoccurring hospitalizations.

CHF affects over 5.7 million Americans resulting in 1.1 million hospitalizations annually and over 50% hospital re-admissions within one year of hospitalization. Readmissions due to recurrent events are preventable and treatable outside the hospital setting with early diagnosis. These preventable and unnecessary readmissions contribute to $18 billion of the $39 billion burden of the disease.

Accel Diagnostics
3500 Fifth Avenue, Suite 203B
Pittsburgh, PA 15213
Tel. + 1 832-641-1900
info@acceldx.com